Shigemi Yoshihara1, Noriko Kanno2, Hironobu Fukuda3, Osamu Arisaka3, Masahiko Arita4, Kunio Sekine5, Koichi Yamaguchi6, Akira Tsuchida7, Yumi Yamada8, Toru Watanabe9, Toshio Shimizu10, Kiyoshi Nishikawa11, Toshiyuki Nishimuta12. 1. Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan. Electronic address: shigemi@dokkyomed.ac.jp. 2. Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan; Department of Pediatrics, Nishikata Hospital, Tochigi, Japan. 3. Department of Pediatrics, Dokkyo Medical University, Tochigi, Japan. 4. Arita Clinic of Pediatrics and Pediatric Allergy, Hiroshima, Japan. 5. Sekine Pediatric Clinic, Chiba, Japan. 6. Department of Pediatrics, The Fraternity Memorial Hospital, Tokyo, Japan. 7. Tsuchida Kodomo Clinic, Kanagawa, Japan. 8. Yamada Gastrointestinal Internal Medicine and Pediatric Clinic, Tochigi, Japan. 9. Watanabe Pediatric Allergy Clinic, Hokkaido, Japan. 10. Shimizu Pediatrics and Allergy Clinic, Saitama, Japan. 11. Nishikawa Clinic, Kagawa, Japan. 12. Department of Pediatrics, National Hospital Organization Shimoshizu National Hospital, Chiba, Japan.
Abstract
BACKGROUND: If asthmatic children cannot obtain sufficient control of their disease, not only do they suffer from asthma symptoms, but the daily life activities of their caregivers are also disrupted. We investigated the effectiveness of an inhaled corticosteroid (ICS) for symptom control in previously ICS-untreated school-aged asthmatic children as well as caregiver treatment satisfaction (CTS). METHODS: A multicenter, open-label, single-arm study on 12-week ICS (budesonide Turbuhaler®) monotherapy was undertaken in subjects aged 5-15 years with bronchial asthma not treated with ICS during the previous 3 months. At 0, 4, 8, and 12 weeks after start of ICS administration, Japanese Pediatric Asthma Control Program (JPAC) scores, and CTS scores were summated and lung function measured. At weeks 0 and 12, questionnaires on caregiver anxiety were also assessed. RESULTS: Seventy-five patients were enrolled, and 69 assessed. Ninety percent of subjects had been treated with asthma controller medication except ICS before study enrollment. JPAC score and CTS score were improved significantly at weeks 4, 8, and 12 (p < 0.001). With regard to CTS, more than half of caregivers showed a perfect score at weeks 8 and 12. There was a significant correlation between JPAC score and CTS score. Lung function and caregiver anxiety were also improved, and good compliance with treatment was observed during the intervention. CONCLUSIONS: If treating ICS-untreated school-aged asthmatic children with uncontrolled symptoms, ICS monotherapy can improve CTS along with improving asthma control.
BACKGROUND: If asthmatic children cannot obtain sufficient control of their disease, not only do they suffer from asthma symptoms, but the daily life activities of their caregivers are also disrupted. We investigated the effectiveness of an inhaled corticosteroid (ICS) for symptom control in previously ICS-untreated school-aged asthmatic children as well as caregiver treatment satisfaction (CTS). METHODS: A multicenter, open-label, single-arm study on 12-week ICS (budesonide Turbuhaler®) monotherapy was undertaken in subjects aged 5-15 years with bronchial asthma not treated with ICS during the previous 3 months. At 0, 4, 8, and 12 weeks after start of ICS administration, Japanese Pediatric Asthma Control Program (JPAC) scores, and CTS scores were summated and lung function measured. At weeks 0 and 12, questionnaires on caregiver anxiety were also assessed. RESULTS: Seventy-five patients were enrolled, and 69 assessed. Ninety percent of subjects had been treated with asthma controller medication except ICS before study enrollment. JPAC score and CTS score were improved significantly at weeks 4, 8, and 12 (p < 0.001). With regard to CTS, more than half of caregivers showed a perfect score at weeks 8 and 12. There was a significant correlation between JPAC score and CTS score. Lung function and caregiver anxiety were also improved, and good compliance with treatment was observed during the intervention. CONCLUSIONS: If treating ICS-untreated school-aged asthmatic children with uncontrolled symptoms, ICS monotherapy can improve CTS along with improving asthma control.
Authors: Hugo Rosado; Catarina Pereira; Jorge Bravo; Joana Carvalho; Armando Raimundo Journal: Int J Environ Res Public Health Date: 2022-06-10 Impact factor: 4.614